Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864259 | 1.00 | ALDH1A1 (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL2045140 | 1.00 | ALDH1A1 (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL29642587 | 1.00 | ALDH1A1 (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL30006288 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL206387 | 0.80 | ALDH1A1 (1.00) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL29642599 | 0.79 | TSHR (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL2227751 | 0.79 | TSHR (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL5484236 | 0.79 | ALDH1A1 (0.67) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL27963505 | 0.79 | CES2 (0.61) | ALDH1A1TSHRCES2CES1TP53 | |
| SCHEMBL5484238 | 0.79 | ALDH1A1 (0.67) | ALDH1A1TSHRCES2CES1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | LYCERA CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2019-09-12 | — | — | US | disclosed |
| WO-2018039539-A1 | INDAZOLYL-L,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2018-03-01 | — | — | WO | disclosed |
| US-8895306-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-8669072-B2 | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-03-11 | — | — | US | disclosed |
| EP-1601354-B1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2013-11-13 | — | — | EP | disclosed |
| EP-1601354-A4 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORPORATION | 2009-06-11 | — | — | US | disclosed |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | HORMANN ROBERT EUGENE | 2008-10-16 | — | — | US | disclosed |
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | RHEOGENE, INC. (DE CORPORATION) | 2007-12-13 | — | — | US | disclosed |
| US-7304162-B2 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1601354-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005017126-A2 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | RHEOGENE, INC. (DE CORPORATION) | 2004-09-02 | — | — | US | disclosed |
| US-5336780-A | 5-amino-1-hydroximoyl pyrazoles | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1994-08-09 | — | — | US | disclosed |
| US-4187099-A | 3-Aryl-4-isothiazolecarboxylic acid and 3-aryl-4-isoxazolecarboxylic acid derivatives and their use as herbicides | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4018645-A | Method of controlling slime during paper manufacture using alpha-chloro-acylbenzaldoxime derivatives | SOMAR MANUFACTURING CO., LTD. (JA) | 1977-04-19 | — | — | US | disclosed |
| US-3968240-A | α-Chloro-o-acylbenzaldoxime derivatives as slime control agents | SOMAR MANUFACTURING CO., LTD. (JA) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287731-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | ALDH1A1 3889/4885TSHR 624/4885CES2 3196/4885 |
| US-20190276447-A1 | INDAZOLYL-1,2,4-THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, TNK2 | ALDH1A1 3126/4885TSHR 2202/4885CES2 3852/4885 |
| US-20080255210-A1 | 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system | NR0B1, NR0B2, NR5A2 | ALDH1A1 3889/4885TSHR 624/4885CES2 3196/4885 |
| US-20040171651-A1 | Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide | NR2E3, ESRRB, NR0B2 | ALDH1A1 4171/4885TSHR 505/4885CES2 2356/4885 |
| US-20090149514-A1 | OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | ESRRB, NR2E3, NR5A1 | ALDH1A1 4104/4885TSHR 476/4885CES2 3037/4885 |
| US-10556898-B2 | Indazolyl-1,2,4-thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease | ROCK1, ROCK2, TNK2 | ALDH1A1 3126/4885TSHR 2202/4885CES2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.